Helicobacter pylori (H. pylori) seropositivity has been inconsistently associated with pancreatic cancer. We, therefore, investigated the association between H. pylori seropositivity and pancreatic cancer in a case-control study nested within Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC) cohort of Finnish male smokers. Pancreatic cancer cases (n = 353) and control subjects (n = 353) were matched on date of baseline serum collection, age at randomization, and follow-up time (up to 23.9 years). We used a multiplex serology assay to determine the sero-status of antibodies against 15 H. pylori-specific antigens in fasting serum samples. Conditional logistic regression was used to calculate the odds ratio (OR) and 95% confidence intervals (CI). Neither targeted H. pylori antigens in serum nor the combination of all was associated with development of pancreatic cancer (combination of all: OR, 0.85; 95% CI, 0.49-1.49). Our results suggest that H. pylori is not a risk factor for pancreatic cancer. © 2013 AACR.
CITATION STYLE
Yu, G., Murphy, G., Michel, A., Weinstein, S. J., Männistö, S., Albanes, D., … Stolzenberg-Solomon, R. Z. (2013). Seropositivity to Helicobacter pylori and risk of pancreatic cancer. Cancer Epidemiology Biomarkers and Prevention, 22(12), 2416–2419. https://doi.org/10.1158/1055-9965.EPI-13-0680
Mendeley helps you to discover research relevant for your work.